Bartosz Hudzik/LinkedIn
May 23, 2026, 16:42
Bartosz Hudzik: Bleeding Risk Alone Should Not Determine Treatment Intensity
Bartosz Hudzik, Associate Profesor at Medical University of Silesia, shared his post a post on X, adding:
“HBR has become synonymous with antithrombotic de-escalation.
Yet bleeding risk alone should not determine treatment intensity.
Many AF, MI, PCI patients classified as HBR remain ischemic-risk dominant, underscoring the need for personalized rather than algorithmic therapy.”
Bartosz Hudzik shared a post on X:
“At EuroPCR 2026, we show that many HBR, AF, MI, PCI patients remain ischemic-risk dominant despite high bleeding risk.
In selected patients, triple antithrombotic therapy may still provide net clinical benefit”
Other posts featuring Bartosz Hudzik on Hemostasis Today.
-
Oct 5, 2026, 09:06Edward Lee Carter: NOTION-4 – HALT and Clinical Outcomes
-
Oct 4, 2026, 15:06Vasiliki Gkalea: Journal of Clinical Medicine Launches Special Issue on Hematologic Thrombosis and Bleeding
-
Oct 4, 2026, 14:55Quentin Brebant: What Defines a High-Quality Red Blood Cell Concentrate?
-
Oct 4, 2026, 14:47Rana Al-Hrout: Recognizing Non-Anemic Iron Deficiency – Why Iron Matters Beyond Hemoglobin
-
Oct 4, 2026, 14:41David McIntosh: International Plasma Awareness Week 2026 – Closing the Global Plasma Gap
-
Oct 4, 2026, 14:33Pete Stibbs: CleanerVac Real-World Study Presented at VIVA and The VEINS 2026
-
Oct 4, 2026, 13:56Maria Elisa Mancuso: EHC 2026 Highlights the Unmet Needs of Women with Bleeding Disorders
-
Oct 4, 2026, 13:53Nirmal Shaji George: Individualizing Anticoagulation in Complex APS and Thrombocytopenia
-
Oct 4, 2026, 13:5210 Posts Not to Miss This Week